Clinical Trial Update: Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PSMA-targeted PET imaging agent 18F-DCFPyL for detecting clinically significant prostate cancer. The trial (NCT03471650) is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pylarify (piflufolastat F-18)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING